News stories about TESARO (NASDAQ:TSRO) have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. TESARO earned a daily sentiment score of 0.06 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 48.7027281002672 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:

A number of research analysts have weighed in on TSRO shares. Cann reaffirmed a “buy” rating and issued a $199.00 price objective on shares of TESARO in a report on Monday, June 5th. Robert W. Baird reaffirmed a “neutral” rating and issued a $140.00 price objective (down previously from $155.00) on shares of TESARO in a report on Thursday. Cowen and Company cut their price objective on shares of TESARO from $145.00 to $124.00 and set a “market perform” rating for the company in a report on Monday, June 19th. Citigroup Inc. reaffirmed a “buy” rating and issued a $216.00 price objective (down previously from $232.00) on shares of TESARO in a report on Saturday, April 22nd. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $183.00 price objective on shares of TESARO in a report on Thursday. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. TESARO currently has an average rating of “Buy” and an average price target of $176.35.

TESARO (NASDAQ:TSRO) opened at 111.85 on Friday. The company’s 50-day moving average is $130.46 and its 200-day moving average is $149.15. The firm’s market capitalization is $6.06 billion. TESARO has a 52-week low of $83.26 and a 52-week high of $192.94.

TESARO (NASDAQ:TSRO) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.52) by $0.30. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The business had revenue of $29.50 million for the quarter, compared to analysts’ expectations of $18.61 million. During the same quarter last year, the business posted ($1.28) earnings per share. The business’s revenue was down 17.6% compared to the same quarter last year. Equities analysts predict that TESARO will post ($8.45) earnings per share for the current year.

In other TESARO news, VP Edward C. English sold 8,500 shares of the firm’s stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the completion of the transaction, the vice president now directly owns 5,396 shares in the company, valued at approximately $748,155.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 40.50% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/tesaro-tsro-receives-coverage-optimism-score-of-0-06/1476242.html.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Insider Buying and Selling by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.